• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Zoetis Releases 2024 Sustainability Progress Update

    6/5/25 9:00:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZTS alert in real time by email
    • Increased colleague-reported volunteer hours by 23%, making a difference for animals, those who care for them, and communities
    • Zoetis Foundation dispersed $11.3 million in grants, including funding for nearly 500 veterinary student scholarships
    • Launched strategic partnerships to address sustainability needs for dairy and beef producers
    • Responded to avian influenza challenges with science-driven solutions
    • Sourced 80.6% of global electricity from renewable sources
    • Advanced sustainable manufacturing with packaging improvements and reduced emissions

    Zoetis published its 2024 Sustainability Progress Update "Advancing Sustainability in Animal Health for a Better Future" to highlight the company's continued progress toward achieving its Driven to Care aspirations. The publication represents Zoetis' fifth year reporting on its purpose-driven actions across three pillars – Communities, Animals and the Planet – that strengthen its business by creating long-term value, enhancing stakeholder trust, and supporting sustainable growth.

    "Zoetis contributes to a healthier future for communities, animals and the planet thanks to our colleagues who demonstrate their commitment to the Driven to Care strategy and are empowered to advance our company's purpose," said Jeannette Ferran Astorga, Executive Vice President, Corporate Affairs, and Chief Sustainability Officer at Zoetis and President of the Zoetis Foundation. "By embedding our sustainability strategy across our business, and through purposeful partnerships with our customers and other stakeholders, our actions address challenges at the intersection of people, animals and the environment."

    Highlights of the company's progress in 2024 include:

    Communities – Care and Collaboration

    • 20,404 hours of community-based volunteer time reported by colleagues, which represents 102% of the company's stated goal and a 23% increase from hours reported in 2023. Zoetis provides paid time off for colleagues to volunteer and support animals, their caregivers, and local communities.
    • The Zoetis Foundation disbursed $11.3 million in grants in 2024 ($26.2 million since 2021), supporting education, well-being, and livelihoods for veterinarians and farmers as well as humanitarian aid and a matching gifts program. The grantmaking in 2024 included $3.5 million in funding that will provide nearly 500 veterinary student scholarships.
    • $8.9 million invested in communities through Zoetis Inc. corporate giving; efforts included vet care access to approximately 322,000 pet owners in need and providing care to approximately 428,000 animals affected by disasters.
    • 86% colleague engagement rate driven by a culture anchored in Core Beliefs; the company's focus on colleagues includes talent development programs, mentorship and coaching, and comprehensive benefits to foster an inclusive workplace where every colleague can thrive.

    Animals – Innovation in Animal Health

    • Launched a strategic partnership with Danone, leveraging Zoetis' genetics expertise to advance the dairy industry's approach to breeding cattle for sustainability. Also, began a research collaboration with AgNext to close data gaps and meet the evolving sustainability needs of the cattle industry.
    • Introduced solutions for Highly Pathogenic Avian Influenza (HPAI) including existing vaccines used to help protect California Condors in the U.S. and trialed on five species of endangered birds in New Zealand.
    • Treated 16.7 million cows and 354.9 million chickens in Sub-Saharan Africa, exceeding goals, through the company's African Livestock Productivity and Health Advancement (A.L.P.H.A. Plus) initiative.

    Planet – The Drive to Protect our Planet

    • Continued progress toward carbon neutrality in the company's own operations, reducing total Scope 1 and 2 emissions by 26.7% from 2023. This reduction was primarily driven by increased renewable energy credits procured through a virtual power purchase agreement.
    • 80.6% of the company's global electricity is from renewable sources. The company's locations covered by renewable electricity include 15 manufacturing sites, its R&D headquarters in Kalamazoo, Michigan, and its international headquarters office in Dublin, Ireland.
    • Installed an 800kW solar array at the Rutherford manufacturing site in Australia – making it Zoetis' eighth location to generate a portion of its power through on-site solar energy.
    • Implemented new sustainable packaging solutions and reduced waste through recycled paper packaging for a cattle vaccine in Europe and replaced single use with reusable pallets and transitioned from air to sea freight in Spain.

    For more detailed disclosures on the company's sustainability programs, practices and policies, please download Zoetis' 2024 Sustainability Progress Update or visit www.zoetis.com/sustainability. Zoetis will continue to share updates on its sustainability activities, including progress against its Driven to Care aspirations, and report annually.

    About Zoetis

    As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company's leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.

    DISCLOSURE NOTICES

    Forward-Looking Statements: This press release and the 2024 Sustainability Progress Update (including the 2024 SASB and ESG Index) contain forward-looking statements which reflect the current views of Zoetis with respect to: our progress toward our Driven to Care aspirations; our business plans or prospects; expectations regarding future operating or financial performance; the plans and future work of the Zoetis Foundation, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned "Forward-Looking Statements and Factors That May Affect Future Results" and "Item 1A. Risk Factors," in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

    All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.

    See the footnotes within our 2024 Sustainability Progress Update for more details regarding all calculations.

    ZTS-COR

    ZTS-IR

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250604519690/en/

    Media Contacts:

    Jennifer Albano

    1-862-399-0810 (o)

    [email protected]

    Laura Panza

    1-973-975-5176 (o)

    [email protected]

    Investor Contacts:

    Steve Frank

    1-973-822-7141

    [email protected]

    Nick Soonthornchai

    1-973-443-2792 (o)

    [email protected]

    Get the next $ZTS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZTS

    DatePrice TargetRatingAnalyst
    7/17/2025$155.00Outperform → Market Perform
    Leerink Partners
    6/18/2025$160.00Buy → Hold
    Stifel
    12/2/2024$215.00Outperform
    Leerink Partners
    7/25/2024$220.00Buy
    BTIG Research
    1/12/2024$195.00 → $215.00Buy
    Stifel
    12/19/2023$230.00Buy
    Jefferies
    12/7/2023$237.00Outperform
    Exane BNP Paribas
    9/6/2023$230.00Buy
    HSBC Securities
    More analyst ratings

    $ZTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs

    Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs. Based on the CVMP's positive opinion, the European Commission is expected to issue a decision during the fourth quarter of 2025, and Zoetis anticipates making Lenivia commercially available in the European Union in 2026. If approved, Lenivia will be a new antibody therapy that reduces OA pain in dogs for three months with one injection through its novel binding properties to nerve grow

    10/10/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Declares Fourth Quarter 2025 Dividend

    The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the fourth quarter of 2025. The dividend will be paid on Tuesday, December 2, 2025, to all holders of record of the Company's common stock as of the close of business on Friday, October 31, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock producers. T

    10/9/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle

    With new label, Dectomax®-CA1 Injectable is the first and only parasite control product with conditional approval to help control economically devastating pest Cochliomyia hominivorax (New World screwworm) Zoetis Inc. today announced that Dectomax®-CA1 Injectable is the first and only parasite control product to receive conditional approval from the U.S. Food and Drug Administration for the prevention and treatment of infestations caused by the larvae of Cochliomyia hominivorax (myiasis), and prevention of reinfestation for 21 days. This conditional approval applies to beef cattle, female dairy cattle less than 20 months of age, pregnant beef cows, newborn calves and bulls. Zoetis is co

    9/30/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    SEC Filings

    View All

    Zoetis Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Zoetis Inc. (0001555280) (Filer)

    10/9/25 4:24:08 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Zoetis Inc. (0001555280) (Filer)

    8/27/25 4:21:54 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Zoetis Inc.

    8-K - Zoetis Inc. (0001555280) (Filer)

    8/18/25 11:43:10 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zoetis downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Zoetis from Outperform to Market Perform and set a new price target of $155.00

    7/17/25 8:01:13 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis downgraded by Stifel with a new price target

    Stifel downgraded Zoetis from Buy to Hold and set a new price target of $160.00

    6/18/25 7:45:54 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Zoetis with a new price target

    Leerink Partners initiated coverage of Zoetis with a rating of Outperform and set a new price target of $215.00

    12/2/24 7:04:18 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

    For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species.  Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o

    1/13/22 10:26:13 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Executive Vice President Fuller Julie

    4 - Zoetis Inc. (0001555280) (Issuer)

    10/14/25 4:27:52 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Executive Vice President Polzer Robert J

    4 - Zoetis Inc. (0001555280) (Issuer)

    10/14/25 4:27:59 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Joseph Wetteny

    4 - Zoetis Inc. (0001555280) (Issuer)

    10/14/25 4:27:47 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Financials

    Live finance-specific insights

    View All

    Zoetis Declares Fourth Quarter 2025 Dividend

    The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the fourth quarter of 2025. The dividend will be paid on Tuesday, December 2, 2025, to all holders of record of the Company's common stock as of the close of business on Friday, October 31, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock producers. T

    10/9/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis to Host Webcast and Conference Call on Third Quarter 2025 Financial Results

    Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, November 4, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay of the webcast will be made available on November 4, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular p

    9/23/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Announces Second Quarter 2025 Results, Raises Full Year 2025 Outlook

    Reports Revenue of $2.5 Billion, Growing 4%, and Net Income of $718 Million, or $1.61 per Diluted Share, Increasing 15% and 18%, Respectively, on a Reported Basis for Second Quarter 2025 Delivers 8% Organic Operational Growth in Revenue and 10% Organic Operational Growth in Adjusted Net Income for Second Quarter 2025 Reports Adjusted Net Income of $783 Million, or Adjusted Diluted EPS of $1.76, for Second Quarter 2025 Raises Full Year 2025 Revenue Guidance to $9.450 - $9.600 Billion with Organic Operational Revenue Growth of 6.5% to 8.0% Following Strong First-Half Performance Raises Full Year 2025 Guidance for Organic Operational Growth in Adjusted Net Income to 5.5% to 7.

    8/5/25 7:00:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Leadership Updates

    Live Leadership Updates

    View All

    Dr. Mark Stetter Elected to Zoetis Board of Directors

    Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He will serve on the Board's Quality and Innovation Committee. "Dr. Stetter brings invaluab

    5/22/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Appoints Jamie Brannan to Newly Created Chief Commercial Officer Role

    New Commercial Organizational Structure to Accelerate Long-Term Growth Strategy in Key Markets and Optimize Global Commercial Operations Zoetis Inc. (NYSE:ZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all commercial markets across the globe for the world's leading animal health company. In this new role, Mr. Brannan will lead an evolved commercial organizational structure that will accelerate the company's long-term growth strategy across key markets, drive greater global commercial collaboration and unlock future growth opportunities. This press release features multimedia. View the full release here: https://www.bu

    11/11/24 9:20:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Appoints Gavin D.K. Hattersley to its Board of Directors

    Molson Coors' President and Chief Executive Officer brings valuable business leadership and global public company experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Gavin D.K. Hattersley, President, Chief Executive Officer and Director of Molson Coors Beverage Company, to its Board of Directors. Mr. Hattersley brings global public company leadership and board experience, including as a current Chief Executive Officer and former Chief Financial Officer of Molson Coors, to the Zoetis Board. He will serve on the Board's Corporate Governance and Sustainability Committee. "Gavin Hattersley brings invaluable experience to our Board as we continue to expand

    4/1/24 4:30:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    2/13/24 5:17:36 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    1/26/24 11:49:41 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    2/9/23 11:37:19 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care